Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation.

Abstract

This study assessed the effect of a 3-month course of pegylated interferon-alpha-2a (Peg-IFN-alpha-2a) in 3 liver transplant patients with chronic active hepatitis E. A virological response was sustained for 6 and 5 months in 2 patients after Peg-IFN-alpha-2a therapy was completed. A relapse was observed in the third patient.

• Authors: Nassim Kamar, Lionel Rostaing, Florence Abravanel, Cyril Garrouste, Laure Esposito, Isabelle Cardeau-Desangles, Jean Michel Mansuy, Janick Selves, Jean Marie Peron, Philippe Otal, Fabrice Muscari, Jacques Izopet
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 50 Issue 5 Pg. e30-3 (Mar 01 2010) ISSN: 1537-6591 [Electronic] United States
• PMID: 20113176 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Polyethylene Glycols
• peginterferon alfa-2a

Topics

• Adult
• Antiviral Agents (therapeutic use)
• Hepatitis E (drug therapy)
• Hepatitis, Chronic (drug therapy)
• Humans
• Interferon alpha-2
• Interferon-alpha (therapeutic use)
• Liver Transplantation
• Male
• Middle Aged
• Polyethylene Glycols (therapeutic use)
• Recombinant Proteins
• Secondary Prevention